eXp Realty Launches in Peru, Creating Unmatched Opportunities for Agents to Build Their Future 21-03-2025, 20:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Unlocking Capital: Over 20k traders unlocked their trading potential with Axi Select 12-12-2024, 18:00